Teligent, Inc., formerly known as Igi Laboratories Inc, functions as a specialized generic pharmaceutical enterprise. Operating under its own brand, the company markets and distributes generic injectable medications throughout the United States and Canada. As of December 31, 2018, its U.S. product offerings encompassed 35 generic topical drugs and four branded generic pharmaceutical items. Beyond its proprietary products, Teligent also provides development, formulation, and manufacturing expertise to the pharmaceutical, over-the-counter (OTC), and cosmetic sectors. The company's strategic focus involves the creation, production, and promotion of its own range of generic pharmaceutical products, available in various delivery forms such as topical, injectable, complex, and ophthalmic preparations. Concurrently, it manages its business segment dedicated to contract manufacturing and formulation services. By the close of 2018, Teligent's future product pipeline included 20 Abbreviated New Drug Applications (ANDAs) that had been filed with the U.S. Food and Drug Administration (FDA) for additional pharmaceutical offerings.